Nov 4 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :
* SEPT-QUARTER CONSOL NET PROFIT 2.24 BILLION RUPEES VERSUS
PROFIT
2.49 BILLION RUPEES YEAR AGO
* CONSENSUS FORECAST FOR SEPT-QUARTER CONSOL NET PROFIT WAS
1.93
BILLION RUPEES -- REFINITIV DATA
* SEPT-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 23.75
BILLION
RUPEES VERSUS 22.66 BILLION RUPEES YEAR AGO
* ALLERGY BUSINESS AT PRE-COVID LEVEL DURING Q2’FY21
* WITH GRADUAL OPENING OF US MARKETS, DEMAND CONDITIONS HAVE
BEGUN
IMPROVING
* CONTINUE TO SEE NEW OPPORTUNITIES IN CDMO, GENERICS,
SPECIALTY
PHARMA
* COVID-19 NOT LIKELY TO HAVE MATERIAL IMPACT ON PERFORMANCE
DURING FY21
* SEE STRONG PHARMA, LSI AND DDDS PERFORMANCE IN H2
* FOR LSI, SEE DOUBLE DIGIT REVENUE GROWTH, SIGNIFICANT
GROWTH IN
EBIDTA FOR FY21
* REMDESIVIR PRODUCTION CAPACITY INCREASED FROM 200,000
VIALS TO
480,000 VIALS PER MONTH
* LAUNCHED REMDESIVIR IN MULTIPLE NATIONS, FILED DOSSIERS IN
'SEVERAL OTHERS'
Source text for Eikon: ID:nBSE70L1sd
Further company coverage: JULS.NS
((bangalore.newsroom@thomsonreuters.com;))